Achieving minimal residual disease (MRD) negativity is an independent prognostic factor for survival in multiple myeloma (MM); however there remain questions about the optimal use of MRD. In a review published in Pathology, the journal of the Royal College of Pathologists of Australasia, researchers outlined implementation challenges, standardization across laboratories and clinical trials, and the integration of MRD assessment into the management of MM.